MarketInOut Stock Screener Log In | Sign Up
 

Vaxcyte Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Vaxcyte Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,951.75 mln
Float145 mln
Earnings Date11/09/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

117.30
Transformational upside

Relative Strength

17 / 100
Significantly lagging

Debt / Equity

0.04
Debt-free

ROE

-36.94
Deeply negative

ROA

-33.24
Deeply negative

Business Description

Vaxcyte is a clinical-stage biotechnology company focused on developing next-generation vaccines to protect against serious bacterial infections. Its pipeline includes several investigational vaccines targeting pneumococcal disease in both children and adults, as well as candidates aimed at Group A Streptococcus, the bacteria behind gum disease, and dysentery-causing Shigella. Founded in 2013 and based in San Carlos, California, the company was previously known as SutroVax before rebranding in 2020.

Key Fundamentals

EPS-7.62
ROE-36.94
ROIC-76.25
ROA-33.24
EBITDA, mln-1,037
EV / EBITDA-6.82
EV / EBIT-6.65

Quote Details

Last 60.43
Change -2.42 (-3.85%)
Open 62.35
Volume 2,062,136
Turnover 124,614,880
Average Volume 3,774,114

Financial Ratios

Leverage Ratio1.14
Current Ratio5.72
Price / Book2.99
Price / Tangible Book2.99
Debt / Equity0.04

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price117.30
Short Ratio12.15
Short % of Float11.68

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.01% 17 / 100   
1 Month 6.2% 90 / 100   
2 Months 8.88% 86 / 100   
6 Months 1.58% 59 / 100   
1 Year 42.15% 90 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog